Compare Biogen Inc (BIIB) vs Fortinet Inc (FTNT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Fortinet Inc — how do they compare? Biogen Inc trades at $204 (market cap $30.13B), while Fortinet Inc trades at $160.64 (market cap $118.78B). The key difference: Fortinet Inc is far larger — about 3.9× Biogen Inc's market cap. Which is the better fit depends on your goals.
| BIIB | FTNT | |
|---|---|---|
Market Cap | $30.13B | $118.78B |
Sector | Health | Technology |
52-Week High | $216.63 | $168.29 |
52-Week Low | $128.93 | $75.23 |
Enterprise Value | $37.20B | $115.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Fortinet (FTNT) trades at $164.21, up 2.86% in the last session, reflecting strong momentum as it approaches its consensus price target of $174.50. The stock exhibits bullish technical signals with consistent earnings beats, including Q2 2026 EPS of $0.90 versus $0.746 expected. Revenue growth remains robust, climbing to $6.80 billion in 2025, with a net income margin of 28.17%. Recent news highlights AI-driven cybersecurity demand as a key growth catalyst.
The outlook is positive, supported by solid fundamentals and analyst optimism, though elevated valuation ratios like a P/E of 57.2 pose risks. Competition and market volatility are concerns, but institutional buying and bullish ratings suggest further upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →
